Jiaan Biotech

Jiaan Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on the discovery and development of innovative multi-specific antibody therapeutics. The company utilizes a proprietary nanobody-based technology platform to engineer biologics with enhanced specificity and potency for treating cancer and immunological disorders. Its lead program, JA001, is a bispecific antibody targeting PD-L1 and 4-1BB designed to provide synergistic anti-tumor activity while minimizing systemic toxicity. Jiaan Biotech's pipeline also includes several early-stage candidates targeting immune checkpoints and tumor-associated antigens to address significant unmet clinical needs in oncology.